tyrosine_kinase_inhibitor

Aug 14, 2026

• 皮膚科
• vascular_biology
• antiangiogenic_therapy
• vegf
• tyrosine_kinase_inhibitor
• bevacizumab
• propranolol

Aug 14, 2026

• 皮膚科
• neoplasms_of_the_skin
• mastocytosis
• mast_cell
• tyrosine_kinase_inhibitor

Aug 14, 2026

• 皮膚科
• neoplasms_of_the_skin
• mastocytosis
• treatment
• tyrosine_kinase_inhibitor
• omalizumab

Aug 14, 2026

• 皮膚科
• vascular_biology
• antiangiogenic_therapy
• vegf
• tyrosine_kinase_inhibitor
• bevacizumab
• propranolol

Aug 14, 2026

• 皮膚科
• neoplasms_of_the_skin
• mastocytosis
• mast_cell
• tyrosine_kinase_inhibitor

Aug 14, 2026

• 皮膚科
• neoplasms_of_the_skin
• mastocytosis
• treatment
• tyrosine_kinase_inhibitor
• omalizumab

Aug 14, 2026

• 皮膚科
• vascular_biology
• antiangiogenic_therapy
• vegf
• tyrosine_kinase_inhibitor
• bevacizumab
• propranolol

Aug 14, 2026

• 皮膚科
• neoplasms_of_the_skin
• mastocytosis
• mast_cell
• tyrosine_kinase_inhibitor

Aug 14, 2026

• 皮膚科
• neoplasms_of_the_skin
• mastocytosis
• treatment
• tyrosine_kinase_inhibitor
• omalizumab